NASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free RPRX Stock Alerts $27.82 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$27.22▼$27.9750-Day Range$27.46▼$31.3352-Week Range$25.92▼$36.19Volume4.68 million shsAverage Volume2.31 million shsMarket Capitalization$16.62 billionP/E Ratio14.72Dividend Yield3.02%Price Target$46.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Royalty Pharma alerts: Email Address Royalty Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside68.0% Upside$46.75 Price TargetShort InterestHealthy3.27% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-2.25Upright™ Environmental ScoreNews Sentiment0.88Based on 10 Articles This WeekInsider TradingN/AProj. Earnings Growth9.37%From $3.95 to $4.32 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.85 out of 5 starsFinance Sector48th out of 844 stocksPharmaceutical Preparations Industry10th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.27% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 2.06%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldRoyalty Pharma pays a meaningful dividend of 3.02%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has only been increasing its dividend for 4 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 19.44% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRoyalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Royalty Pharma is -2.25. Previous Next 2.7 News and Social Media Coverage News SentimentRoyalty Pharma has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Royalty Pharma this week, compared to 4 articles on an average week.Search InterestOnly 18 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 19 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.72% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Royalty Pharma are expected to grow by 9.37% in the coming year, from $3.95 to $4.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 14.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 14.72, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 62.24.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Royalty Pharma Stock (NASDAQ:RPRX)Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More RPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPRX Stock News HeadlinesApril 20, 2024 | finance.yahoo.comRoyalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21April 19, 2024 | globenewswire.comRoyalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024April 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 17, 2024 | seekingalpha.comRoyalty Pharma declares $0.21 dividendApril 17, 2024 | finance.yahoo.comRoyalty Pharma Declares Second Quarter 2024 DividendApril 17, 2024 | globenewswire.comRoyalty Pharma Declares Second Quarter 2024 DividendApril 15, 2024 | americanbankingnews.comRoyalty Pharma plc (NASDAQ:RPRX) Receives $46.75 Average PT from BrokeragesApril 14, 2024 | nasdaq.comRelative Strength Alert For Royalty PharmaApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 14, 2024 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) Price Target Cut to $38.00April 11, 2024 | investorplace.com3 Pharma Stocks to Sell in April Before They Crash & BurnApril 9, 2024 | investorplace.comBillionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You've Never Heard Of)April 9, 2024 | investorplace.comApril's Hidden Gems: 3 Overlooked Stocks to Freshen Up Your PortfolioApril 5, 2024 | nasdaq.comJanuary 2025 Options Now Available For Royalty Pharma (RPRX)March 30, 2024 | finance.yahoo.comRoyalty Pharma plc's (NASDAQ:RPRX) Stock Has Shown A Decent Performance: Have Financials A Role To Play?March 27, 2024 | investorplace.comThe Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your PortfolioMarch 16, 2024 | ca.finance.yahoo.comRPRX Dec 2024 17.500 callMarch 16, 2024 | ca.finance.yahoo.comRPRX Oct 2024 40.000 putMarch 11, 2024 | msn.comFDA rejects Viatris/Mapi long-acting version of Teva's CopaxoneMarch 7, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - RPRXFebruary 28, 2024 | finance.yahoo.comRoyalty Pharma to Present at TD Cowen’s 44th Annual Health Care ConferenceFebruary 28, 2024 | globenewswire.comRoyalty Pharma to Present at TD Cowen's 44th Annual Health Care ConferenceFebruary 19, 2024 | uk.news.yahoo.comEntertainment firm director hauled before courts for breaking rulesFebruary 18, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Royalty Pharma plc's (NASDAQ:RPRX) Yearly ReportFebruary 17, 2024 | finance.yahoo.comRoyalty Pharma Full Year 2023 Earnings: EPS: US$2.54 (vs US$0.098 in FY 2022)February 16, 2024 | markets.businessinsider.comGoldman Sachs Reaffirms Their Buy Rating on Royalty Pharma (RPRX)February 16, 2024 | msn.comRoyalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesSee More Headlines Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Ex-Dividend for 3/15 Dividend2/15/2024Dividend Payable3/15/2024Today4/23/2024Next Earnings (Confirmed)5/09/2024Ex-Dividend for 6/14 Dividend5/16/2024Dividend Payable6/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees51Year Founded1996Price Target and Rating Average Stock Price Target$46.75 High Stock Price Target$57.00 Low Stock Price Target$38.00 Potential Upside/Downside+68.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.89 Trailing P/E Ratio14.72 Forward P/E Ratio7.04 P/E GrowthN/ANet Income$1.13 billion Net Margins48.22% Pretax Margin72.20% Return on Equity26.93% Return on Assets15.93% Debt Debt-to-Equity Ratio0.61 Current Ratio7.90 Quick Ratio7.90 Sales & Book Value Annual Sales$2.36 billion Price / Sales7.06 Cash Flow$4.51 per share Price / Cash Flow6.17 Book Value$16.88 per share Price / Book1.65Miscellaneous Outstanding Shares597,430,000Free Float485,595,000Market Cap$16.62 billion OptionableOptionable Beta0.45 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Pablo Gerardo Legorreta (Age 59)Founder, Chairman of the Board & CEO Mr. Terrance P. CoyneExecutive VP & CFOMr. George Wingate Lloyd (Age 64)Executive VP of Investments & Chief Legal Officer Comp: $4.35MMr. Christopher Hite (Age 57)Vice Chairman & Executive VP Comp: $4.35MDr. Marshall Jonathan Urist M.D.Ph.D., Executive VP and Head of Research & InvestmentsMr. Arthur Richard McGivern J.D.Executive Vice President of Investments & General CounselMr. Ashwin Pai M.D.Executive Vice President of InvestmentsMs. Kristin Stafford (Age 41)Senior VP & Chief Accounting Officer Mr. Eric Cornelius SchneiderSenior VP & Chief Technology OfficerDr. James Folmar Reddoch Ph.D. (Age 54)Executive VP of Investments & Chief Scientific Officer Comp: $3.4MMore ExecutivesKey CompetitorsThe Carlyle GroupNASDAQ:CGKENYSE:BEKEShinhan Financial GroupNYSE:SHGBrookfield Asset ManagementNYSE:BAMLoewsNYSE:LView All CompetitorsInsiders & InstitutionsRaymond James & AssociatesBought 560,897 shares on 4/22/2024Ownership: 0.131%Compound Global Advisors LLCSold 82,906 shares on 4/22/2024Ownership: 0.066%Sumitomo Mitsui Trust Holdings Inc.Sold 87,266 shares on 4/19/2024Ownership: 0.156%New Century Financial Group LLCBought 35,908 shares on 4/19/2024Ownership: 0.006%Park Place Capital CorpSold 588 shares on 4/18/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions RPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Royalty Pharma stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPRX shares. View RPRX analyst ratings or view top-rated stocks. What is Royalty Pharma's stock price target for 2024? 4 brokerages have issued twelve-month price objectives for Royalty Pharma's stock. Their RPRX share price targets range from $38.00 to $57.00. On average, they predict the company's stock price to reach $46.75 in the next twelve months. This suggests a possible upside of 68.0% from the stock's current price. View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts. How have RPRX shares performed in 2024? Royalty Pharma's stock was trading at $28.09 at the start of the year. Since then, RPRX stock has decreased by 1.0% and is now trading at $27.82. View the best growth stocks for 2024 here. When is Royalty Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RPRX earnings forecast. How can I listen to Royalty Pharma's earnings call? Royalty Pharma will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) posted its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.12. The biopharmaceutical company had revenue of $736 million for the quarter, compared to analyst estimates of $702.90 million. Royalty Pharma had a trailing twelve-month return on equity of 26.93% and a net margin of 48.22%. How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma? Royalty Pharma announced a quarterly dividend on Wednesday, April 17th. Stockholders of record on Friday, May 17th will be paid a dividend of $0.21 per share on Friday, June 14th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Thursday, May 16th. Read our dividend analysis for RPRX. Is Royalty Pharma a good dividend stock? Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 3.02%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 19.44% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RPRX. What ETFs hold Royalty Pharma's stock? ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include Tema Global Royalties ETF (ROYA), iShares U.S. Pharmaceuticals ETF (IHE), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Simplify Health Care ETF (PINK), Formidable ETF (FORH), Fidelity Disruptive Medicine ETF (FMED) and First Trust Health Care AlphaDEX Fund (FXH). What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO). When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Royalty Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.16%), Raymond James & Associates (0.13%), Los Angeles Capital Management LLC (0.12%), Compound Global Advisors LLC (0.07%), Overbrook Management Corp (0.04%) and Alaska Permanent Fund Corp (0.01%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston and Terrance P Coyne. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RPRX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
